Experimental Hematology
Volume 35, Issue 2 , Pages 297-304 , February 2007

Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells

  • Parviz Kokhaei

      Affiliations

    • Immune and Gene Therapy Lab, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
    • Drs. Kokhaei and Palma contributed equally to this work.
    • ,
  • Marzia Palma

      Affiliations

    • Immune and Gene Therapy Lab, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
    • Drs. Kokhaei and Palma contributed equally to this work.
    • ,
  • Lotta Hansson

      Affiliations

    • Immune and Gene Therapy Lab, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
    • Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden
    • ,
  • Anders Österborg

      Affiliations

    • Immune and Gene Therapy Lab, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
    • Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden
    • ,
  • Håkan Mellstedt

      Affiliations

    • Immune and Gene Therapy Lab, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
    • Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden
    • Corresponding Author InformationOffprint requests to: Håkan Mellstedt, M.D., Ph.D., Department of Oncology (Radiumhemmet), Karolinska University Hospital Solna, SE-17176, Stockholm, Sweden
    • ,
  • Aniruddha Choudhury

      Affiliations

    • Immune and Gene Therapy Lab, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Received 18 May 2006 ,Revised 31 July 2006 ,Accepted 10 October 2006.

References 

  1. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955–959
  2. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev. 1998;12:1073–1085
  3. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene. 2002;21:564–579
  4. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 2002;21:4338–4348
  5. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015
  6. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–791
  7. Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J Virol. 1994;68:3410–3414
  8. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921–1929
  9. Harrington L, Zhou W, McPhail T, et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 1997;11:3109–3115
  10. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785–795
  11. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85:2315–2320
  12. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445–452
  13. Trentin L, Ballon G, Ometto L, et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol. 1999;106:662–668
  14. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103:375–382
  15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  16. Kokhaei P, Choudhury A, Mahdian R, et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia. 2004;18:1810–1815
  17. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the International ImMunoGeneTics database. Nucleic Acids Res. 1999;27:209–212
  18. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2006;55:1553–1564
  19. Kokhaei P, Rezvany MR, Virving L, et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia. 2003;17:894–899
  20. Spisek R, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2001;50:417–427
  21. Fischer K, Mackensen A. The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods. 2003;31:135–142
  22. Tchirkov A, Chaleteix C, Magnac C, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol. 2004;15:1476–1480
  23. Verstovsek S, Giles FJ, O'Brien S, et al. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res. 2004;28:707–711
  24. Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer. 2003;88:593–598
  25. Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood. 2005;105:4807–4812
  26. Norrback KF, Roos G. Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer. 1997;33:774–780
  27. Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol. 2003;15:75–80
  28. Arai J, Yasukawa M, Ohminami H, et al. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood. 2001;97:2903–2907
  29. Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97:4796–4801
  30. Tajima K, Ito Y, Demachi A, et al. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer. 2004;110:403–412
  31. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10:828–839
  32. Parkhurst MR, Riley JP, Igarashi T, et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10:4688–4698
  33. Gaudernack G, Buanes T, Meo M, et al. Clinical trials of a peptide based vaccine targeting telomerase [abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2003;Abstract 666.
  34. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 2005;23:413–419
  35. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257–265
  36. Spaner DE, Hammond C, Mena J, Foden C, Deabreu A. A phase I/II trial of oxidized autologous tumor vaccines during the “watch and wait” phase of chronic lymphocytic leukemia. Cancer Immunol Immunother. 2005;54:635–646
  37. Hus I, Rolinski J, Tabarkiewicz J, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:1621–1627
  38. Rezvany MR, Jeddi-Tehrani M, Rabbani H, et al. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol. 2000;111:230–238
  39. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica. 2002;87:989–1001

PII: S0301-472X(06)00658-8

doi: 10.1016/j.exphem.2006.10.006

Experimental Hematology
Volume 35, Issue 2 , Pages 297-304 , February 2007

Article Tools

* Image Usage & Resolution